Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses

Area of Science:

• Oncology
• Virology
• Cancer Biology

Background:

• Current cancer therapies struggle to eradicate tumors due to the protective tumor stroma.
• The tumor stroma comprises cancer-associated fibroblasts, extracellular matrix, vasculature, and macrophages, promoting tumor progression.
• These stromal components create a pro-tumoral niche that hinders therapeutic efficacy.

Purpose of the Study:

• To review the interactions between oncolytic viruses (OVs) and tumor stromal components.
• To explore the potential of OVs in simultaneously targeting tumor cells and the tumor stroma.
• To outline strategies for enhancing stromal targeting by OVs.

Main Methods:

• Comprehensive literature review of studies on oncolytic virotherapy and tumor stroma.
• Analysis of native and genetically modified oncolytic viruses.
• Examination of interactions between OVs and cancer-associated fibroblasts, extracellular matrix, tumor vasculature, and tumor-associated macrophages.

Main Results:

• Oncolytic viruses (OVs) can effectively target and disrupt various tumor stromal components.
• OVs promote their own replication and spread by interacting with the stroma.
• OV-stroma interactions contribute to systemic anti-tumor immunity and enhanced therapeutic outcomes.
• Genetically modified OVs offer improved strategies for targeting tumor stroma.

Conclusions:

• Oncolytic viruses represent a promising therapeutic platform for simultaneously targeting both malignant cells and the tumor microenvironment.
• Targeting the tumor stroma with OVs can overcome therapeutic resistance and improve treatment efficacy.
• Further research into OV-stroma interactions can lead to novel and more effective cancer therapies.